This paper is only available as a PDF. To read, Please Download here.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.J Clin Psychopharmacol. 1995; 15: 428-434
- Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: Clinical and behavioral findings.Arch Gen Psychiatry. 1991; 48: 603-610
- The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.Arch Gen Psychiatry. 1994; 51: 486-493
- The effects of CI-988 on CCK-4-panic in healthy volunteers.in: Presented at the annual meeting of the ACNP. 1994
- The diagnostic utility of lactate sensitivity in panic disorder.Arch Gen Psychiatry. 1990; 47: 277-284
- Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys.Neuropeptides. 1991; 19 (suppl): 75-78
- The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist.Br J Pharmacol. 1991; 104: 239-245
- Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.in: Proc Natl Acad Sci USA. 88. 1991: 1130-1133
- Cognitive factors in lactate-induced anxiety.Behav Res Ther. 1986; 24: 677-680
- Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic in panic disorder (PD) patients.Psychopharmacol Bull. 1994; 30: 644
Received in revised form: March 6, 1996
Received: November 24, 1995
This study was funded by a grant from Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company.
© 1996 Society of Biological Psychiatry. Published by Elsevier Inc.